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Bradykinesia is the most disabling motor symptom of Parkinson’s disease (PD). The 
sequence effect (SE), a feature of bradykinesia, refers to the rapid decrement in ampli-
tude and speed of repetitive movements (e.g., gait, handwriting) and is a major cause 
of morbidity in PD. Previous research has revealed mixed results regarding the role of 
dopaminergic treatment in the SE. However, external cueing has been shown to improve 
it. In this study, we aimed to characterize the SE systematically and relate this phenom-
enon to the energetic cost of movement within the context of cost–benefit framework of 
motor control. We used a dynamic isometric motor task with auditory pacing to assess 
the SE in motor output during a 15-s task segment in PD patients and matched con-
trols. All participants performed the task with both hands, and without and with visual 
feedback (VF). Patients were also tested in “on”- and “off”-dopaminergic states. Patients 
in the “off” state did not show higher SE compared to controls, partly due to large 
variance in their performance. However, patients in the “on” state and in the absence of 
VF showed significantly higher SE compared to controls. Patients expended higher total 
motor energy compared to controls in all conditions and regardless of their medication 
status. In this experimental situation, the SE in PD is associated with the cumulative 
energetic cost of movement. Dopaminergic treatment, critical for internal triggering of 
movement, fails to maintain the motor vigor across responses. The high motor cost may 
be related to failure to incorporate limbic/motivational cues into the motor plan. VF may 
facilitate performance by shifting the driving of movement from internal to external or, 
alternatively, by functioning as a motivational cue.
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inTrODUcTiOn
Bradykinesia, one of the cardinal manifestations of Parkinson’s disease (PD), means slowness of 
movement. It is the most disabling symptom and a complex phenomenon with different compo-
nents (1). In the clinical setting, bradykinesia is assessed during repetitive sequential movements 
(e.g., finger tapping). The amplitude and/or speed of the movements rapidly diminishes with each 
repetition. This phenomenon is known as the “sequence effect” (SE) and seems unique to PD among 
other parkinsonian syndromes (2, 3). The SE is an important source of morbidity in daily activities of 
PD patients, including handwriting, gait, and speech (3–5), for which dopaminergic treatment falls 
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short. Several behavioral paradigms have been used to character-
ize the SE and reports on the role of dopaminergic treatment are 
heterogeneous. Some studies demonstrated that while certain 
components of bradykinesia responded well to dopaminergic 
treatment, the SE did not (6–8).
Although SE is a well-known clinical observation, the under-
lying pathophysiology has not been fully characterized. While 
one cannot exclude the contribution of peripheral fatigue to the 
SE, there are two observations that point to a central mechanism: 
(1) the onset of the decrement is rather abrupt occurring within 
seconds and (2) it can be reversed with visual or motivational 
cueing. Various central mechanisms for bradykinesia have been 
proposed that are also relevant in understanding the SE:
(1) Insufficient motor energy was considered an important 
factor in bradykinesia. Electrophysiological studies have 
demonstrated that movements are not given the full motor 
command that they require (9, 10) due to inadequate corti-
cal drive to the muscle (11, 12). This deficit improves with 
dopaminergic treatment.
(2) Deficit in scaling was also thought to contribute to the 
underscaling of the desired movement (13–15).
(3) Bradykinesia and SE can also be considered part of “central 
fatigue” (16). Patients with central fatigue have difficulty 
with sustained performance in serial tasks. This is also a 
fundamental problem in PD and patients often report feeling 
as if their “battery is running down” (17).
(4) Finally, in recent years, behavioral studies and computa-
tional models have operationalized bradykinesia and related 
problems within the “cost–benefit” framework. According 
to this framework, PD patients assign implicitly (i.e., out of 
awareness) a higher energetic cost to a motor task, therefore, 
“scale down” their motor vigor (speed, amplitude, or force) 
as an implicit adaptive response in order to optimize motor 
effort (18–20). This suggests that PD patients are capable of 
demonstrating a motor performance comparable to that of 
controls, but at a higher cost, i.e., they would have to exert 
higher effort than controls.
In this study, we approached the SE as a central problem of 
motor energy and aimed to characterize it systematically using a 
repetitive motor task in two conditions: (1) patients and matched 
healthy volunteers (HVs) were tested using a demanding dynamic 
isometric task with and without visual feedback (VF) on their 
performance and (2) patients were also tested in “off ”- and “on”-
dopaminergic states.
We hypothesized that (1) PD patients in off-dopaminergic 
state will show significantly higher SE compared to HVs, (2) 
dopaminergic treatment will not improve SE, but VF will, and (3) 
the energetic cost of motor performance will be higher in patients 
compared to HVs regardless of medication status.
MaTerials anD MeThODs
Participants
Thirteen right-handed PD patients and 13 right-handed age- and 
gender-matched HVs participated in the study after giving written 
informed consent in accordance with the Combined NeuroScience 
Institutional Review Board of the National Institutes of Health. 
Patients were recruited through the Parkinson’s Disease Clinic at 
the National Institute of Neurological Disorders and Stroke. One 
patient tested positive for the LRRK2 gene and was excluded. One 
HV was also excluded due to an error in data recording. The data 
of 12 PD subjects (5 F, average age 63.0 ± 6.4) and 12 HVs (6 F, 
average age 62.7 ± 6.9) were included in the analysis.
All participants underwent physical and neurological 
examinations. The following exclusion criteria applied to all 
participants: the presence of any neurological or psychiatric 
disorder (other than PD and comorbid depression or anxiety 
for the PD group), or a medical condition that might affect 
the central nervous system, and active alcohol or illicit drug 
abuse. The diagnosis of PD was established according to the 
UK Parkinson’s Disease Society Brain Bank Clinical Diagnosis 
Criteria (21). All patients had bradykinesia and at least one of 
the following impairments: rigidity, resting tremor, or postural 
instability. The side of disease onset was left in half, and right in 
the other half of patients. Patients were assessed using the Unified 
Parkinson’s Disease Rating Scale (UPDRS) (22) and the Hoehn 
and Yahr (H&Y) scale (23). Patients with a UPDRS tremor score 
>1 in either hand and with an H&Y score >3 were not included. 
Patients were tested first off of any dopaminergic medication in the 
morning. Immediately upon completion of the “off ” testing, they 
were given their regular dose of levodopa/carbidopa and other 
dopaminergic medications, and tested again at the peak of their 
“on” state. The “off ” state was defined as at least a 12-h washout 
period for immediate-release levodopa/carbidopa and dopamine 
receptor agonists, and 24 h washout for MAO-B inhibitors and 
extended-release formulations of levodopa/carbidopa and dopa-
mine receptor agonists. All patients were responsive to levodopa/
carbidopa (within 80 ± 34 min). The “on” state was established by 
patients’ subjective report and objective neurological exam. The 
levodopa equivalent daily dose was calculated using the formula 
reported by Tomlinson et al. (24).
The Edinburgh Handedness Inventory and neuropsychologi-
cal tests were also administered on the day of testing to all par-
ticipants including the Montreal Cognitive Assessment test (25) 
and Mini Mental State Examination (26) to rule out dementia, 
Spielberger State and Trait Anxiety Inventory (27), and Beck 
Depression Inventory-II (28). The Fatigue Severity Scale (29) was 
administered only to patients.
Dynamic isometric Task
The SE and its response to dopaminergic treatment and 
VF were tested in a dynamic isometric task using a hand 
clench dynamometer (Biopac Systems, Inc.) (Figure S1 in 
Supplementary Material). This is a rigid device that weighs 323 g, 
is 17.78 cm × 5.59 cm × 2.54 cm in size, and has an isometric 
range of 0–90 kg. It measures the applied force in voltage which is 
then converted to kilograms (nominal output: 782 μV/kg).
Participants sat comfortably in a chair in front of a computer 
holding the dynamometer in their hand with their forearm sup-
ported. The grip force of both hands was measured separately at 
the beginning of each test session. Participants were instructed 
to give their full grip force for 3 s, and the maximum voluntary 
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contraction (MVC) was calculated as the average of 10 peak val-
ues. Fifty percent of the MVC was computed (MVC50) and used 
as the target force. Participants squeezed the dynamometer with 
each hand, repetitively, at MVC50 paced by a metronome cue 
at 1.25 Hz. Movement velocity covaries with the exerted force. 
By using external pacing, we aimed to keep the movement rate 
steady and examined the decrement in force across repetitions. 
The 1.25  Hz frequency was chosen based on previous studies 
(30) and our pilot data that showed that patients were able to 
match it.
There were two additional conditions: (1) all participants 
performed the task without VF (VF−) by solely relying on their 
perception of effort required to reach the MVC50, and then with 
VF (VF+) by monitoring their performance on the computer 
display. (2) Patients were tested twice, first in off- then in on-
dopaminergic state at least 1 h apart.
The VF item had the shape of a speedometer. The midpoint 
represented the MVC50 target. In the VF+ condition, the needle 
of the speedometer moved up toward the target in real time 
with participant’s each squeeze. In the VF− condition, needle 
movement toward the target was simulated by the computer. 
This was done to match the visual input in both conditions, and 
participants were aware that the computer display did not reflect 
their performance in the VF− condition.
Initially, all participants received training at MVC50 with 
VF to form an internal representation of the required force for 
MVC50. After training, the VF− session started. The VF+ ses-
sion followed immediately after the VF− with the same hand. 
Each session lasted 90 s. In the end of each session, the MVC was 
measured again to obtain a measure of fatigue.
Modeling the se
The first squeeze was discarded as it was highly variable and 
seemed to reflect participants’ attempt to calibrate their force. 
The rest of the dataset was smoothed using a sliding window 
of five time points. Previous studies and our pilot data demon-
strated that the decrement requires ~15 s to occur (8, 30, 31). 
For consistency, we chose the first 20 squeezes (after the first was 
discarded) as the segment to examine for SE (short segment). 
This segment corresponded to ~15 s in all subjects (Table S1 in 
Supplementary Material). The force applied in each squeeze was 
normalized to the initial MVC. The peak of each squeeze was 
extracted using the peakfinder.m code in Matlab 2013b. Then, 
a linear slope was fitted to these peaks. The whole 90 s segment 
corresponding to 100 squeezes was analyzed separately to evalu-
ate overall fatigue.
We also computed the area under the curve (AUC) of each 
peak using the trapezoidal numerical integration function in 
Matlab with unit spacing from the previous minimum to the 
current maximum peak. The AUC is equivalent to the integrated 
force over time, which corresponds to the motor impulse. We 
defined the motor energy as the capacity to create the motor 
impulse and used the sum of AUC across 20 squeezes as a measure 
of total motor energy expended during the short segment. The 
sum of AUC across the whole segment was analyzed separately. 
The change in AUC across each squeeze was also computed 
(Supplementary Material).
statistical analyses
The primary outcome measures were the slope values fitted to the 
peaks and the sum of AUC.
Slope and Sum of AUC
A critical observation was that the initial force, which was sup-
posed to be MVC50, varied considerably between groups, there-
fore, had to be included in the main analyses as a covariate. To 
compare the primary outcome measures slope and sum of AUC 
between the groups, we performed ANCOVAs with dependent 
variables slope and sum of AUC, fixed factors (1) group (HV vs. 
PD-off, HV vs. PD-on, and PD-off vs. PD-on), (2) hand (left/
right), and (3) feedback (VF−/VF+); and initial force as the 
covariate. These analyses were employed for both short and whole 
segments separately.
Initial Force
Additionally, we used a repeated measure ANOVA to compare 
the initial force (i.e., the second squeeze) values between HV 
vs. PD-off, HV vs. PD-on, and PD-off vs. PD-on using feedback 
(VF+/VF−) and hand (left/right) as within-subject, and group as 
between-subject factors.
Maximum Voluntary Contraction
The first MVC (MVC1) and final MVC (MVC2) values were also 
compared with the same repeated measures ANOVA approach 
used for the initial force analysis. This analysis was performed to 
assess overall fatigue at the end of 90 s.
Clinical
The Montreal Cognitive Assessment test, Mini Mental State 
Examination, Spielberger State and Trait Anxiety Inventory, 
and Beck Depression Inventory-II scores were compared using 
two-sample t-tests between the PD and HV groups. The clinical 
measures, including the UPDRS total, UPDRS-III motor exam, 
Spielberger State and Trait Anxiety Inventory, Beck Depression 
Inventory-II, and Fatigue Severity Scale, were also used as regres-
sors in a multiple regression analysis to assess their correlations 
with the dependent variables peak slopes and sum of AUC of the 
short segment during VF− and VF+ conditions in PD-off and 
PD-on.
All statistical analyses were performed using SPSS version 22.
resUlTs
clinical
Demographic and clinical data are summarized in Table 1. The 
average levodopa equivalent daily dose for the PD group was 
932 ± 514 mg. The average Montreal Cognitive Assessment test 
score was 28.3 ± 2.3 in the HV and 27.9 ± 1.9 in the PD group. 
The average Mini Mental State Examination score was 29.5 ± 1.0 
in the HV and 29.5 ± 0.9 in the PD group. The average Spielberger 
State and Trait Anxiety raw scores were 22.2 ± 2.8 and 26.8 ± 7.3 
in the HV group, respectively, and 29.3 ± 9.2 and 34.0 ± 10.2 in the 
PD group, respectively. These scores were within the score range 
of a normative sample between the ages 50 and 69  years (27). 
TaBle 1 | Demographic and clinical data.
age sex s/T BDi Fss leDD (mg) h&Y off/on UPDrs-t off/on UPDrs-iii off/on
HV1 62 M 27/– 0
HV2 54 F 24/22 1
HV3 52 F 20/23 9
HV4 56 F 22/36 0
HV5 68 F 22/37 2
HV6 75 F 21/22 2
HV7 57 F 20/21 0
HV8 65 M 23/40 8
HV9 61 M 28/28 1
HV10 69 M 20/24 0
HV11 67 M 20/22 0
HV12 67 M 20/20 0
PD1 66 M 21/– 7 33 1650 2/2 60/45 35/26
PD2 54 F 23/27 3 48 667 2/2 57/33 30/18
PD3 56 F 23/25 2 33 600 2.5/2.5 53/21 32/13
PD4 55 F 45/47 13 42 1093 3/3 52/43 28/19
PD5 68 M 25/29 8 25 2125 2.5/2 39/26 27/16
PD6 75 F 30/32 3 50 1083 2/2 42/32 28/21
PD7 58 F 33/38 9 50 975 2.5/2.5 51/38 33/26
PD8 66 M 30/26 6 38 670 2/2 50/38 31/24
PD9 63 M 20/31 9 45 220 2/2 41/37 26/22
PD10 70 M 49/37 8 58 700 2.5/2 65/56 39/32
PD11 63 M 24/25 9 37 700 2/2 64/59 42/38
PD12 62 M 29/57 7 18 700 2/2 52/41 33/26
HV, healthy volunteers; PD, Parkinson’s disease patients; S/T: Spielberger Anxiety Inventory State/Trait; BDI, Beck Depression Inventory-II; FSS, Fatigue Severity Scale; LEDD, 
levodopa equivalent daily dose; H&Y, Hoehn and Yahr; UPDRS, Unified Parkinson’s Disease Rating Scale; t, total score; III, motor examination score; off/on, off/on dopaminergic 
medication; M, male; F, female.
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The average Beck Depression Inventory-II score was 1.9 ± 3.2 in 
the HV and 7.0 ± 3.1 in the PD group (0–13 indicates minimal 
depression) (28). The average Fatigue Severity Scale score for the 
PD group was 39.8 ± 11.4, which was above the cut-off 36 and 
indicated significant fatigue (29).
The comparison of these scores (p value adjusted for five 
comparisons: 0.05/5  =  0.01) revealed a significant difference 
in the BDI-II scores between PD and HV groups (p = 0.0007). 
There was a trend for significance in the state anxiety scores 
(p = 0.018).
The PD group had an average H&Y score of 2.25 ± 0.3 in the 
“off ” and 2.17 ± 0.3 in the “on” state. The average total UPDRS 
score was 52.1 ± 8.5 in the “off ” and 39.1 ± 10.9 in the “on” state. 
The average UPDRS-III motor exam score was 32.0 ± 4.8 in the 
“off ” and 23.4 ± 6.9 in the “on” state.
Behavioral
The mean and SD values of the initial forces, MVCs, and slope 
and sum of AUC values for the short segment are listed in Table 2 
(see also Figure 1).
Initial Force
Only a single significant main effect of group was observed in both 
HV vs. PD-off and HV vs. PD-on comparisons, namely, the HV 
group showed significantly higher initial force [F(1,22) = 12.974, 
p = 0.002 and F(1,22) = 10.001, p = 0.005, respectively]. There 
was no significant main effect of hand or feedback, and no 
interaction. The initial force did not differ significantly in the PD 
group between “off ” and “on” states.
Short Segment
Peak Slopes
The ANCOVA in the HV vs. PD-off comparison revealed only 
a significant main effect of the initial force [F(8,87) =  38.947, 
p = 0.000]. In the HV vs. PD-on comparison, again a significant 
main effect of the initial force [F(8,87) =  49.709, p =  0.000], 
as well as a significant group  ×  feedback interaction were 
observed [F(8,87) =  7.334, p =  0.008]. Planned pairwise com-
parisons revealed that the VF− condition was a significant 
factor [F(1,87) = 8.864, p = 0.004] and PD-on had significantly 
more negative slopes in the VF− condition compared to HVs 
[F(1,87) = 4.391, p = 0.04].
In the PD-off vs. PD-on comparison, the initial force dem-
onstrated a significant main effect [F(8,87) = 56.43, p = 0.000], 
and there was a significant three-way interaction between medi-
cation status ×  feedback ×  hand [F(8,87) =  4.026, p =  0.048]. 
However, planned pairwise comparisons did not show significant 
differences.
Sum of AUCs
The ANCOVA in the HV vs. PD-off and HV vs. PD-on com-
parisons showed a significant main effect of the initial force 
[F(8,87) =  6.525, p =  0.012 and F(8,87) =  10.999, p =  0.001, 
respectively] and a significant main effect of the group 
[F(8,87) = 16.872, p = 0.000 and F(8,87) = 14.127, p = 0.000, 
respectively]. The PD group had a significantly higher sum of 
AUC in “off ” and “on” states compared to the HV group. There 
was no significant main effect of hand or feedback, or any 
interaction.
TaBle 2 | Behavioral data.
hV PD-off PD-on
l r l r l r
initial force (% MVc)
VF− 0.69 ± 0.11 0.75 ± 0.13 0.57 ± 0.15 0.54 ± 0.13 0.62 ± 0.14 0.56 ± 0.15
VF+ 0.67 ± 0.13 0.69 ± 0.13 0.54 ± 0.08 0.60 ± 0.18 0.56 ± 0.12 0.57 ± 0.09
slope
VF− −0.002 ± 0.006 −0.002 ± 0.005 −0.004 ± 0.006 0.001 ± 0.012 −0.002 ± 0.009 −0.003 ± 0.006
VF+ −0.003 ± 0.004 −0.004 ± 0.005 0.000 ± 0.003 −0.002 ± 0.006 0.000 ± 0.003 0.000 ± 0.003
sum of aUc
VF− 103.5 ± 26.6 99.5 ± 26.8 118.1 ± 44.8 110.6 ± 30.0 123.4 ± 43.9 102.8 ± 51.0
VF+ 93.1 ± 35.1 96.0 ± 40.7 128.2 ± 38.8 128.7 ± 39.6 122.7 ± 38.4 118.6 ± 39.1
MVc1 (kg)
VF− 15.31 ± 6.67 16.02 ± 6.75 17.84 ± 8.16 18.74 ± 6.49 17.08 ± 6.23 18.00 ± 9.53
VF+ 15.67 ± 6.62 15.62 ± 7.38 18.94 ± 6.79 18.41 ± 8.08 16.55 ± 6.37 18.56 ± 9.09
MVc2 (kg)
VF− 15.95 ± 7.05 15.96 ± 7.16 16.16 ± 5.73 17.06 ± 6.82 17.46 ± 8.17 17.11 ± 8.92
VF+ 14.78 ± 6.46 16.53 ± 7.25 15.88 ± 4.96 16.46 ± 6.02 15.84 ± 7.59 18.53 ± 9.23
The mean and SD values of the initial force as percentage of the MVC, initial and final MVC, and slope and sum of AUC values for the short segment are shown.
HV, healthy volunteers; PD, Parkinson’s disease patients; off/on, off/on dopaminergic medication; L, left hand; R, right hand; AUC, area under the curve; MVC, maximum voluntary 
contraction; 1, initial; 2, final; VF−/+, visual feedback, without and with.
The slope and sum of AUC values belong to the short segment.
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In the PD-off vs. PD-on comparison, only the initial force 
showed a significant main effect [F(8,87) = 51.453, p = 0.000]. 
There was no significant main effect of medication status, hand 
or feedback, or any interaction.
Whole Segment
Peak Slopes
Both in the HV vs. PD-off and HV vs. PD-on comparisons, there 
was a significant main effect of the initial force [F(8,87) = 4.138, 
p =  0.045 and F(8,87) =  6.129, p =  0.015, respectively] and 
feedback [F(8,87) =  22.589, p =  0.000 and F(8,87) =  24.642, 
p = 0.000, respectively]. The slopes were less negative in the VF+ 
condition.
In the PD-off vs. PD-on comparison, there was only a sig-
nificant main effect of feedback [F(8,87) =  34.145, p =  0.000] 
demonstrating less negative slope in the VF+ condition.
Sum of AUCs
In the HV vs. PD-off comparison, the initial force [F(8,87) = 9.297, 
p =  0.003], group [F(8,87) =  29.271, p =  0.000] and feedback 
[F(8,87) =  6.115, p =  0.015] showed significant main effects. 
There was no significant interaction between any factors. The sum 
of AUC was higher in the VF+ condition. PD-off showed higher 
sum of AUC in all conditions.
In the HV vs. PD-on comparison, there was a significant 
main effect of the initial force [F(8,87) = 6.503, p = 0.013], group 
[F(8,87) =  14.605, p =  0.000], and feedback [F(8,87) =  4.161, 
p = 0.044]. There was no significant interaction between any fac-
tors. The sum of AUC was higher in the VF+ condition. PD-on 
showed higher sum of AUC in all conditions.
In the PD-off vs. PD-on comparison, there was a significant 
main effect of the initial force [F(8,87) = 50.181, p = 0.000], feed-
back [F(8,87) = 10.723 p = 0.002], and hand [F(8,87) = 5.348, 
p =  0.023]. There was no significant interaction between any 
factors. The sum of AUC was higher in the VF+ condition, 
and the left hand demonstrated higher sum of AUC across all 
conditions.
MVC1 and MVC2
One patient could complete only 75 squeezes with left hand 
during “on” in the VF− condition and the matched HV did not 
have the MVC2 of the right hand in the VF− condition due to 
recording failure. Both subjects were excluded from the MVC 
analysis.
The MVC1 values did not differ significantly between the 
groups in the HV vs. PD-off, HV vs. PD-on, and PD-off vs. 
PD-on comparisons. There was also no significant main effect 
of feedback or hand, or any interactions. The MVC2 values 
also did not differ significantly between the groups in the HV 
vs. PD-off comparison. There was no significant main effect 
of feedback or hand, or any interactions. In the HV vs. PD-on 
comparison, there was a significant hand × feedback interaction 
[F(1,20) = 8.404, p = 0.009]. Pairwise comparisons showed that 
the left hand [F(1,20) = 8.058, p = 0.01] and the VF+ condition 
[F(1,20) = 10.467, p = 0.004] were significant factors demonstrat-
ing that the left hand MVC2 value was significantly smaller in the 
VF+ condition.
In the PD-off vs. PD-on comparison of the MVC2 values, there 
was a significant three-way interaction between hand ×  feed-
back × medication status [F(1,20) = 4.453, p = 0.048]. Planned 
pairwise comparisons showed significant medication status 
(PD-on) ×  feedback (VF+) [F(1,20) =  7.695, p =  0.012] and 
medication status (PD-on) × hand (left hand) [F(1,20) = 5.152, 
p = 0.034] interactions. Taken together, these interactions dem-
onstrated significantly lower MVC2 in the left hand of PD-on 
during the VF+ condition.
FigUre 1 | Behavioral data of the short segment. White columns: left hand, black columns: right hand. Error bars: SD. HV, healthy volunteers; PD, Parkinson’s 
disease patients; off/on, off/on dopaminergic medication; VF−/+, visual feedback, without and with; MVC, maximum voluntary contraction; sum AUC, sum of area 
under the curve. (a) Mean ± SD of the initial force as a percentage of the MVC. (B) Mean ± SD of slopes of the short segment. (c) Mean ± SD of the sum of AUC.
6
Tinaz et al. Sequence Effect in Parkinson’s Disease
Frontiers in Neurology | www.frontiersin.org May 2016 | Volume 7 | Article 83
Correlations with the Clinical Measures
The multiple regression analysis with the clinical measures was 
not significant for the peak slopes or the sum of AUC of the short 
segment during VF− or VF+ conditions in PD-off or PD-on.
DiscUssiOn
Our main findings can be summarized as follows: (1) the groups 
were well matched in their MVC. (2) The magnitude of the initial 
squeeze played a significant role in the degree of the decre-
ment. (3) HV group exhibited significantly higher initial force 
compared to PD-off and PD-on in all conditions. (4) PDs in the 
“on” state showed significantly higher SE compared to HVs in the 
VF− condition. (5) PDs demonstrated a higher sum of AUC for 
the short segment compared to HVs, and this was independent 
of feedback and medication status. (6) Both groups benefited 
comparably from feedback in the whole segment showing less 
decrement in force and also showed higher sum of AUC with 
feedback. (7) PDs demonstrated a higher sum of AUC for the 
whole segment compared to HVs independent of feedback and 
medication status.
Next, we interpret these findings and discuss their potential 
neurophysiological underpinnings.
energetic cost and Dopamine
Contrary to our hypothesis, we did not observe significantly 
higher SE in PD-off compared to the HVs in the VF− condition. 
Instead, PD-on showed significantly higher SE in the VF− condi-
tion compared to HVs in line with our second hypothesis stating 
dopaminergic treatment would not improve SE.
The initial force is an important determinant of SE and was 
significantly higher in HVs in all conditions. However, initial 
force alone does not explain the lack of significant SE in PD-off 
compared to the HVs because PDs in “on” and “off ” states were 
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comparable with regard to the initial force. We think that the 
large variance in slope values in PD-off, especially concerning 
the right hand in the VF− condition (Supplementary Material), 
is probably the main factor that might obscure a true difference 
in SE means between HV and PD-off.
Reports on the role of dopaminergic treatment in reversing 
the SE vary according to the experimental design and outcome 
measures of interest. Behavioral studies using static force para-
digms (e.g., hand-grip) demonstrated decline in force over time 
in PD patients (7, 32, 33). This decline improved with levodopa 
in some studies (32, 33), but not in others (7). Isotonic force 
tasks (e.g., finger tapping) revealed a rate-dependent decline in 
the amplitude of the movement, which showed no or minimal 
improvement with levodopa (30, 31). Decreased speed was found 
to improve with levodopa (8, 31); however, fatigue, defined as 
decrement in speed or amplitude, did not improve (8).
In our experiment, we controlled for the speed component by 
externally pacing each squeeze with a metronome at a pace which 
patients were able to maintain in “off ” and “on” states. However, 
the decrement in force was not reversed with dopaminergic treat-
ment. We propose the following explanations for this observa-
tion: (1) relatively high energetic cost of each squeeze for patients 
and (2) failure of dopaminergic treatment to energize repetitive 
squeezes over time.
(1) We defined motor energy as the capacity to create the motor 
impulse needed to reach the peak of each squeeze. Our results 
demonstrated that the energetic cost (i.e., sum of AUC) of 
performance in the short segment was significantly higher 
in PDs compared to HVs regardless of the actual motor 
output, feedback condition, or medication status. In the 
cost–benefit models of motor control, the energetic cost was 
introduced as a variable and considered a major determinant 
of speed in discrete movements (18, 19). Higher sensitivity 
to movement energy cost (i.e., reduced motor vigor) was 
shown in PD patients in discrete reaching tasks (18, 19). 
PD patients were able to make fast and accurate movements 
in a reaching task, but required more attempts to reach the 
speed criterion. This was interpreted as a higher sensitivity 
to movement energy cost in PD (18). Our results are in line 
with this interpretation and suggest that the energetic cost of 
maintaining motor performance at a steady pace over time is 
higher in PD patients compared to HVs.
(2) Dopaminergic treatment improves the motor cortical drive 
to the muscle (11, 12). Dopamine is also known to increase 
motor response vigor (e.g., speed, force) and energize 
behavior (34, 35). For instance, dopamine depletion in 
the nucleus accumbens or anterior cingulate cortex in rats 
made the animals choose low-effort actions to obtain food, 
but without altering their food preference or intake (36). 
Similarly, PD patients chose low-effort actions to obtain 
rewards which improved with dopaminergic medication 
(37). Moreover, Niv et al. proposed a model to account for the 
motor response vigor in the context of reward/effort tradeoff 
in free-operant behavior (38). In this model, the average 
rate of reward was encoded by tonic dopamine levels. For 
instance, when the average rate of reward is high (high tonic 
dopamine level), then one will move faster. On the other 
hand, if the average rate of reward is low (dopamine deple-
tion), then there is no urgency to move faster. According to 
this model, one could argue that optimal tonic dopamine 
levels can invigorate motor response by improving the cost/
benefit ratio. However, as our results demonstrate, dopa-
mine replacement does not seem sufficient to overcome the 
energetic cost of a continuous motor task and prevent SE. 
We cannot separate out the role of tonic vs. phasic dopamine 
levels in our study because pharmacological treatment most 
likely influences both types of signaling. We think that the 
continuous task probably demands a high rate of dopamine 
signaling which cannot be sustained by an overall increase 
in dopamine levels following replacement. This also suggests 
that other neurotransmitter systems (e.g., serotonin) might 
be involved (39).
energetic cost and Visual Feedback
We cannot rule out the potential role of peripheral fatigue during 
the performance of the short segment in PDs. However, several 
observations pertaining to the whole segment point to additional 
mechanisms that might be involved.
Patients and HVs did not differ significantly in their perfor-
mance across the whole segment. Furthermore, the initial and 
final MVC values were also not significantly different between 
the groups suggesting that the task demands were comparable 
for both groups. In addition, both groups were able to improve 
their performance with feedback throughout the whole segment 
even though the VF+ runs immediately followed the VF− runs 
of the same (i.e., already “tired”) hand. In other words, excessive 
peripheral fatigue does not explain the SE in PD-on in the VF− 
condition during the short segment of the task. We think that 
the SE may reflect the difficulty in sustaining motor performance 
when the required effort has to be motivated and generated 
internally.
Initiation and sequential performance require an internally 
driven mechanism to prepare the emotive, motor and sensory 
apparatus (“cues”) (16). The limbic and motor basal ganglia– 
cortical loops may serve the integration of these “cues.” 
Activation in specific components of the basal ganglia-motor 
cortical circuits as well as in the amygdala has been demonstrated 
in the performance recovery phase of a demanding motor task 
(40). Therefore, it is conceivable that the disrupted integration 
in the basal ganglia–cortical loops in PD may lead to defective 
cue production for the subsequent set of responses and result 
in SE. As discussed in the previous section, performance has an 
energetic cost which needs to be balanced by motivation to be 
sustained. Taken within this cost–benefit context, the defective 
cue production might be the neural mechanism underlying 
the inability to overcome the cumulative energetic cost of a 
repetitive task (41).
The role of VF becomes particularly important at this point. 
In fact, VF+ reversed the SE in PD-on by providing an external 
reference. This result is consistent with previous reports of sus-
tained improvement in stride length in PD patients in response 
to VF (4, 42, 43). One possible mechanism for this improvement 
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is that VF directly facilitates the implementation of motor 
commands by the motor cortices via the parietal cortex (44). 
An alternative, but not mutually exclusive route, for VF might 
be the cerebellum. The cerebellum also integrates visual–motor 
information and plays a major role in the predictive timing and 
coordination of isometric grip forces (45). Finally, VF can also 
be considered a motivational/attentional cue because, despite 
the increased motor energy expenditure, VF drives continued 
performance by presenting the goal explicitly and allowing online 
monitoring of performance. It should be noted that the effect of VF 
was also observed in the performance of all subjects throughout 
the whole segment. All subjects improved and maintained their 
performance with VF despite the higher energetic cost associ-
ated with the VF+ condition, which was even higher for PDs. 
This finding is consistent with the observations that individuals 
may still be capable of carrying on the desired task depending on 
motivational/attentional factors (46).
Finally, we did not find a correlation between our primary 
outcome measures (slope and sum of AUC) and clinical 
measures of fatigue, mood, or disease severity. One explana-
tion would be that these measures might be too broad and not 
sensitive enough to explain the SE. Alternatively, SE is a unique 
phenomenon that is at least partially independent of fatigue as 
we have demonstrated, and it is observed at every stage of disease 
including mild-to-moderate severity. Furthermore, mood may 
not have been a significant contributor to the SE because the 
depression scores of the patients were in the minimal depres-
sion range and the anxiety scores were within the normal range 
suggesting that our PD cohort did not have a significant mood 
disorder.
In conclusion, we think that SE in PD is a motoric manifesta-
tion of a complex phenomenon that includes energetic, atten-
tional, and motivational factors. Dopaminergic treatment fails to 
maintain motor vigor across subsequent responses implicating 
the involvement of other neurotransmitters. The cumulative 
motor cost may be related to failure to incorporate limbic/moti-
vational cues into the motor plan. VF bypasses this bottleneck by 
providing the necessary cues externally.
limitations
Two points should be kept in mind in interpreting the results 
of this study: (1) the unequal variances in performance between 
groups and (2) the initial force as a significant factor. The large 
variance in PD-off, especially in the VF− condition, may have 
obscured a difference in means. The initial force is a significant 
independent determinant of performance and ideally, should be 
controlled for in the experiment.
Furthermore, patients were tested twice on the same day 
always in the same order, first “off ” and then “on” medication. 
However, there was at least an hour between the two sessions, and 
in light of our results, general fatigue or learning as confounding 
factors during “on” testing seems unlikely. Future studies should 
address these issues more directly by testing the HVs twice.
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